title: ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.
abstract: BACKGROUND
  Studies have observed an association between the ABO blood group and risk of certain malignancies. However, no studies of the association with hepatocellular carcinoma (HCC) risk are available. We conducted this hospital-based case-control study to examine the association with HCC in patients with chronic hepatitis B (CHB).
  
  
  METHODS
  From January 2004 to December 2008, a total of 6275 consecutive eligible patients with chronic hepatitis B virus (HBV) infection were recruited. 1105 of them were patients with HBV-related HCC and 5,170 patients were CHB without HCC. Multivariate logistic regression models were used to investigate the association between the ABO blood group and HCC risk.
  
  
  RESULTS
  Compared with subjects with blood type O, the adjusted odds ratio (AOR) for the association of those with blood type A and HCC risk was 1.39 [95% confidence interval (CI), 1.05-1.83] after adjusting for age, sex, type 2 diabetes, cirrhosis, hepatitis B e antigen, and HBV DNA. The associations were only statistically significant [AOR (95%CI) = 1.56(1.14-2.13)] for men, for being hepatitis B e antigen positive [AOR (95%CI) = 4.92(2.83-8.57)], for those with cirrhosis [AOR (95%CI), 1.57(1.12-2.20)], and for those with HBV DNA≤10(5)copies/mL [AOR (95%CI), 1.58(1.04-2.42)]. Stratified analysis by sex indicated that compared with those with blood type O, those with blood type B also had a significantly high risk of HCC among men, whereas, those with blood type AB or B had a low risk of HCC among women.
  
  
  CONCLUSIONS
  The ABO blood type was associated with the risk of HCC in Chinese patients with CHB. The association was gender-related.
authors.affiliation: Division of Liver Disease, Jinan Infectious Disease Hospital, Shandong University, Jinan, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Cui-Hua
authors.initials: CH
authors.lastname: Yu
authors.forename: Jin-Hong
authors.initials: JH
authors.lastname: Yu
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.forename: Shuang-Shuang
authors.initials: SS
authors.lastname: Xie
authors.forename: Wen-Wen
authors.initials: WW
authors.lastname: Li
authors.forename: Xia
authors.initials: X
authors.lastname: Yang
authors.forename: Wen-Bo
authors.initials: WB
authors.lastname: Fan
authors.forename: Zhong-Tao
authors.initials: ZT
authors.lastname: Gai
authors.forename: Shi-Jun
authors.initials: SJ
authors.lastname: Chen
authors.forename: Naoya
authors.initials: N
authors.lastname: Kato
mesh_terms: D000017:ABO Blood-Group System; D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000150:complications*; D016022:Case-Control Studies; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012306:Risk
chemical_list: D000017:ABO Blood-Group System